IMUNON, Inc. (IMNN) Cites 14.7-Month OS Signal; Phase 3 Advancing
IMUNON reported a 14.7-month median OS difference (45.1 vs 30.4 months) in its 112-patient Phase 2 OVATION 2 study and said its pivotal Phase 3 OVATION 3 is enrolling, with two pre-planned interim OS analyses that could enable an earlier BLA if thresholds are met.Material DetailsContext by AI Analy…